0 12 Relationship relationship NN 13 20 between between IN 21 33 IkappaBalpha IkappaBalpha NNP 34 46 constitutive constitutive JJ 47 57 expression expression NN 57 58 , , , 59 67 TNFalpha TNFalpha NNP 68 77 synthesis synthesis NN 77 78 , , , 79 82 and and CC 83 92 apoptosis apoptosis NN 93 95 in in IN 96 108 EBV-infected ebv-infected JJ 109 123 lymphoblastoid lymphoblastoid JJ 124 129 cells cell NNS 129 130 . . . 132 134 In in IN 135 140 order order NN 141 143 to to TO 144 154 understand understand VB 155 158 the the DT 159 163 role role NN 164 166 of of IN 167 176 NF-kappaB NF-kappaB NNP 177 179 in in IN 180 183 EBV EBV NNP 184 198 transformation transformation NN 199 201 we we PRP 202 206 have have VBP 207 218 established establish VBN 219 225 stably stably RB 226 237 transfected transfecte VBN 238 250 IkappaBalpha IkappaBalpha NNP 251 255 into into IN 256 270 lymphoblastoid lymphoblastoid JJ 271 276 cells cell NNS 276 277 . . . 278 281 Two two CD 282 288 clones clone NNS 289 293 were be VBD 294 302 obtained obtain VBN 303 305 in in IN 306 311 which which WDT 312 315 the the DT 316 320 loss loss NN 321 323 of of IN 324 333 NF-kappaB NF-kappaB NNP 334 341 binding binding NN 342 350 activity activity NN 351 361 correlated correlate VBD 362 366 with with IN 367 370 the the DT 371 383 constitutive constitutive JJ 384 394 expression expression NN 395 397 of of IN 398 401 the the DT 402 412 transgenic transgenic JJ 413 425 IkappaBalpha IkappaBalpha NNP 425 426 . . . 427 434 Protein protein NN 435 442 latency latency NN 443 453 expression expression NN 454 457 was be VBD 458 468 determined determine VBN 469 471 by by IN 472 491 immunocytochemistry immunocytochemistry NN 491 492 . . . 493 503 Expression expression NN 504 506 of of IN 507 514 surface surface NN 515 522 markers marker NNS 522 523 , , , 524 540 intracytoplasmic intracytoplasmic JJ 541 548 content content NN 549 551 of of IN 552 561 cytokines cytokine NNS 562 566 cell cell NN 567 572 cycle cycle NN 573 581 analysis analysis NN 582 587 after after IN 588 592 BrdU BrdU NNP 593 606 incorporation incorporation NN 607 610 and and CC 611 614 DNA dna NN 615 623 staining staining NN 624 628 with with IN 629 638 propidium propidium NN 639 645 iodide iodide NN 646 650 were be VBD 651 658 studied study VBN 659 661 by by IN 662 666 flow flow NN 667 676 cytometry cytometry NN 676 677 . . . 678 688 Percentage percentage NN 689 691 of of IN 692 701 apoptotic apoptotic JJ 702 707 cells cell NNS 708 711 was be VBD 712 722 determined determine VBN 723 725 by by IN 726 733 in-situ in-situ FW 734 743 labelling labelling NN 744 746 of of IN 747 750 DNA DNA NNP 751 757 strand strand NN 758 764 breaks break NNS 764 765 . . . 766 768 No no DT 769 782 significative significative JJ 783 790 changes change NNS 791 793 in in IN 794 797 EBV EBV NNP 798 805 latency latency NN 806 809 nor nor CC 810 812 in in IN 813 817 cell cell NN 818 825 surface surface NN 826 832 marker marker NN 833 843 expression expression NN 844 847 was be VBD 848 853 found find VBN 853 854 . . . 855 857 In in IN 858 866 contrast contrast NN 866 867 , , , 868 884 intracytoplasmic intracytoplasmic JJ 885 893 TNFalpha TNFalpha NNP 894 900 levels level NNS 901 905 were be VBD 906 914 strongly strongly RB 915 922 reduced reduce VBN 923 925 in in IN 926 937 transfected transfecte VBN 938 944 clones clone NNS 944 945 . . . 946 957 Furthermore furthermore RB 957 958 , , , 959 961 30 30 CD 961 962 % % NN 963 965 of of IN 966 978 IkappaBalpha IkappaBalpha NNP 979 990 transfected transfecte VBN 991 996 cells cell NNS 997 1001 were be VBD 1002 1011 apoptotic apoptotic JJ 1012 1017 after after IN 1018 1019 8 8 CD 1020 1021 h h NN 1022 1024 of of IN 1025 1033 TNFalpha TNFalpha NNP 1034 1043 treatment treatment NN 1043 1044 . . . 1045 1049 This this DT 1050 1060 correlated correlate VBD 1061 1065 with with IN 1066 1067 a a DT 1068 1074 strong strong JJ 1075 1084 reduction reduction NN 1085 1087 of of IN 1088 1092 BrdU BrdU NNP 1093 1106 incorporation incorporation NN 1107 1112 after after IN 1113 1115 24 24 CD 1116 1117 h h NN 1118 1120 of of IN 1121 1129 TNFalpha TNFalpha NNP 1130 1139 treatment treatment NN 1139 1140 . . . 1141 1143 No no DT 1144 1150 effect effect NN 1151 1154 was be VBD 1155 1159 seen see VBN 1160 1164 with with IN 1165 1168 non non JJ 1169 1180 transfected transfecte VBN 1181 1186 cells cell NNS 1187 1189 or or CC 1190 1194 with with IN 1195 1200 cells cell NNS 1201 1212 transfected transfecte VBN 1213 1217 with with IN 1218 1219 a a DT 1220 1227 control control NN 1228 1235 plasmid plasmid NN 1235 1236 . . . 1237 1240 Our our PRP$ 1241 1248 results result NNS 1249 1256 suggest suggest VBP 1257 1261 that that IN 1262 1265 the the DT 1266 1274 TNFalpha TNFalpha NNP 1275 1279 gene gene NN 1280 1285 could could MD 1286 1288 be be VB 1289 1292 one one CD 1293 1295 of of IN 1296 1299 the the DT 1300 1307 targets target NNS 1308 1310 of of IN 1311 1320 NF-kappaB NF-kappaB NNP 1321 1323 in in IN 1324 1327 EBV EBV NNP 1328 1336 infected infected JJ 1337 1342 cells cell NNS 1343 1346 and and CC 1347 1351 that that IN 1352 1361 NF-kappaB NF-kappaB NNP 1362 1370 protects protect VBZ 1371 1383 EBV-infected ebv-infected JJ 1384 1389 cells cell NNS 1390 1394 from from IN 1395 1404 apoptosis apoptosis NN 1405 1412 induced induce VBN 1413 1415 by by IN 1416 1424 TNFalpha TNFalpha NNP 1424 1425 , , , 1426 1431 which which WDT 1432 1435 may may MD 1436 1442 favour favour VB 1443 1446 the the DT 1447 1460 proliferative proliferative JJ 1461 1467 effect effect NN 1468 1470 of of IN 1471 1475 this this DT 1476 1484 cytokine cytokine NN 1484 1485 . . .